Navigation Links
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/27/2008

SAN CARLOS, Calif., Feb. 27, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today the company's financial results for the fourth quarter and year ended December 31, 2007.

Revenue totaled $65.8 million in the fourth quarter of 2007 compared to $69.9 million in the fourth quarter of 2006. For the year ended December 31, 2007, Nektar reported total revenue of $273.0 million compared to $217.7 million in 2006.

Cash, cash equivalents, and short-term investments were $482.4 million at December 31, 2007 compared to $452.6 million at September 30, 2007.

Nektar reported a net income of $39.0 million or $0.42 per share in the fourth quarter of 2007 compared to a net loss of $38.9 million or $0.43 per share in the same period of 2006.

For the twelve months ended December 31, 2007, our net loss was $32.8 million or $0.36 per share compared to a net loss of $154.8 million or $1.72 per share in the same period in 2006.

"We have built a focused, efficient and driven company with an impressive and growing proprietary pipeline," said Howard W. Robin, President and CEO of the company. "We have moved multiple programs into Phase 2 clinical development, entered into valuable new collaborations, and ended the year in a solid financial position. We expect to build on this momentum in 2008."

Mr. Robin will host a conference call today for analysts and investors beginning at 2:00 p.m. Pacific time to discuss the company's performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, http://www.nektar.com. The web broadcast of the confer
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...A jury of 8 people in the Western District of Penn...n pain and suffering for a medical malpractice cas...icia Nocera of Thomas E. Crenney and Associates, L...ta Monestersky and against the Uniontown Hospital....al hysterectomy at age 18. , ...
(Date:11/8/2009)...twork of Hispanic health advocates committed to ac..., WASHINGTON, Nov. 7 "...hey have heard the voice of America,s families by .... Now the Senate must deliver, without delay, on t... Dr. Jane L. Delgado, President and CEO of the Nat...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
(Date:11/8/2009)...ows Who Sides With Working Families vs. Insurance ...re-USNewswire/ -- On the heels of an historic late...good, balanced health care reform bill, the Pennsy...te,s U.S. representatives voted on HR 3962, the Af...egislation, which passed Saturday evening by a vot...
(Date:11/7/2009)...PRNewswire-USNewswire/ -- Karen Ignagni, President...), released the following statement today on House...y support comprehensive health care reform, and we...a complete overhaul of how health insurance is pro...overage, elimination of pre-existing condition exc...
Breaking Medicine News(10 mins):Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2
... Zealand President Murray Dear is not happy with t...al check up. The statistics show that only 60% of ...l check up for diabetics, which is a state, funded...cations such as amputation, kidney failure, heart ...
... on the release of funds amounting $367 million fo...Malaria has been lifted. Uganda was funded with mo...t. // The Global community banned the funding...sed after the global community was reassured by Ug...
...a breakthrough, scientists present the first proof...ng cause of the common cold.// So, if your mo...tching a cold, it seems she may have had a point. ...ar in this week’s The Oxford Journal of Family Pra...
...rs of the popular Ortho Evra birth control patch a...isk of blood clots and other serious side effects ...d and Drug Administration has warned. Accord...ch would have similar risks as the pill. But the w...
...ew study appearing in the November 1, 2005 issue o...t a new gene profile may help in predicting how pa...to aggressive chemotherapy. // In many patients... of chemotherapy-resistant cancer cells, most pati...
...efinitive link has been established between age-re...sms underlying the disease process. The finding ha...ium //called Chlamydia pneumoniae in the diseased ...hers found C. pneumoniae in the diseased eye tissu...
Other Medicine News:Health News:Scientist affirm mother’s advice 2Health News:FDA Warns Against Birth-Control Patch 2Health News:Genetic Profile To Predict Ovarian Cancer Prognosis 2
(Date:11/6/2009)...VILLE, Pa., Nov. 6 Philips Respiro...se Control and Prevention (CDC) to raise awareness... sleep insufficiency. The CDC,s release of the fir... differences in sleeplessness is a milestone in qu..., As a long-time educator, industry leader and sle...
(Date:11/6/2009)...N, Nov. 6 Cyberonics, In...ny will report financial results for the second qu...ding April 30, 2010 on Wednesday, November 18, 200...erence call to discuss those results on Thursday, ...ear 2010 Second Quarter Results Conference Call In...
(Date:11/6/2009)...RIS, November 6 , - Trial...olid for the,Treatment of Multi-Resistant Staphylo..., a speciality pharmaceutical company focused on t...designed to overcome the significant global,proble...s most advanced oral,antibacterial NXL103 (flopris...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model 28SM 29 Scale 53058 1Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model 28SM 29 Scale 53058 2Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model 28SM 29 Scale 53058 3Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model 28SM 29 Scale 53058 4Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model 28SM 29 Scale 53058 5Wounded Warrior Project 28WWP 29 Pushes for Senate Bill to Assist Family Caregivers of the Most Severely Injured Veterans 53055 1Wounded Warrior Project 28WWP 29 Pushes for Senate Bill to Assist Family Caregivers of the Most Severely Injured Veterans 53055 2First U K Stem Cell Awareness Rally to Take Place in Manchester England on August 9th 2009 13249 1First U K Stem Cell Awareness Rally to Take Place in Manchester England on August 9th 2009 13249 2First U K Stem Cell Awareness Rally to Take Place in Manchester England on August 9th 2009 13249 3
...EA806 Shown to Produce Statistically Significant, ...d in Phase 1 Clinical Study, - Phase 2 Efficacy S...f 2008, CARLSBAD... RDEA ) today announced the initiation of a new c...eatment of gout. Gout, also known,as metabolic art...
...Jim Kim joins teleconference to release report wit... are "the best chance we,ve ever had to,build comp..., NEW YORK AND CAPE TOWN, South Africa, Nov.27 ,T...(ITPC), a group of 1,000,treatment activists from ...port on scale up of AIDS services: Missing the Tar...
Other Medicine Technology:Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout 2Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout 3Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout 4Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout 5Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout 6New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 2New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 3New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 4
...tyles. Each style has multiple sizes. Style 1 is b...e available non-sterile and sterile, and are packa...es are mirror-image meaning that they are each mad...e normally inserted through a transaxillary (armpi...
... Software offers a complete Patient Data Managemen...rent diagnostic tests for your patients. Designed ..., our software offers capabilities such as EMR int...tral database (MS SQL Server) and Access database ...
...advanced and refined system that runs on your conv...ything you need to get up and running in minutes i... the IQmark Digital ECG are dramatically lower tha...n including the cost of the computer), and yet thi...
...e often thought of as very aggressive and producin...TCA peels are very different from the standard. Ou...gredients including lactic acid, ascorbic acid (vi...laic acids to produce dramatic results without the...
Medicine Products: